Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Trial of Prednisone, Abiraterone, Cabazitaxel and Enzalutamide (PACE) for Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT03110588 is registered in ClinicalTrials.gov with University of Alabama at Birmingham as lead sponsor.

NCT NCT03110588
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03110588 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Trial of Prednisone, Abiraterone, Cabazitaxel and Enzalutamide (PACE) for Metastatic Castration-resistant Prostate Cancer (mCRPC)
Lead sponsor
University of Alabama at Birmingham
Phase
Phase 1
Overall status
Withdrawn
Start date
May 9, 2018
Completion date
December 18, 2019
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic prostate cancer